神経疾患診断市場：製品別、病態別、エンドユーザー別、地域別、機会、予測、2017年～2031年

世界の神経疾患診断の市場規模は、予測期間の2024年～2031年に7.56%のCAGRで拡大し、2023年の79億3,000万米ドルから2031年には142億1,000万米ドルに成長すると予測されています。神経障害の有病率の上昇と投資家や市場関係者の関心の高まりにより、神経障害診断の市場需要は予測数年で飛躍的に伸びると予測されています。

医学用語としての神経障害は、人体全体に分布する神経や脊髄のほか、脳に影響を及ぼす障害を指します。このような障害は、脳、脊髄、その他の神経の構造的、生化学的、電気的な異常により、さまざまな症状を呈することがあります。そのような障害の例としては、麻痺、筋力低下、協調性の低下、感覚の喪失、発作、錯乱、疼痛、意識レベルの乱れなどがあります。例えば、The Lancet Neurologyの報告によると、世界中の3人に1人以上が神経疾患の影響を受けており、これは現在、世界中で病気や障害の主な原因となっていることを意味します。脳疾患、障害、傷害は世界中のすべての人に影響を及ぼしますが、神経学的死亡や健康被害の80％以上は低所得国や中所得国で発生していると推定されています。高所得国では、人口10万人当たりの神経疾患専門医の数が、低・中所得国の70倍にも上ります。糖尿病ニューロパチーやアルツハイマー病などの神経疾患の流行により、神経疾患診断の必要性が高まっています。これらの要因により、予測期間中、世界の神経障害診断市場が活性化すると予想されます。

当レポートでは、世界の神経疾患診断市場について調査し、市場の概要とともに、製品別、病態別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の神経疾患診断市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 製品別
  • 病態別
  • エンドユーザー別
  • 地域別

第5章 北米の神経疾患診断市場の見通し、2017年～2031年

第6章 欧州の神経疾患診断市場の見通し、2017年～2031年

第7章 アジア太平洋の神経疾患診断市場の見通し、2017年～2031年

第8章 南米の神経疾患診断市場の見通し、2017年～2031年

第9章 中東・アフリカの神経疾患診断市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 輸出入の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

第17章 市場の動向と発展

第18章 規制枠組みとイノベーション

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 主要参入企業トップ10の情勢
  • Koninklijke Philips N.S.
  • Thermo Fisher Scientific, Inc.
  • CANON MEDICAL SYSTEMS CORPORATION.
  • FUJIFILM Holdings Corporation.
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • Siemens AG.
  • Mitsar Co, LTD.
  • NIHON KOHDEN CORPORATION.
  • General Electric Company.

第22章 戦略的提言

第23章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 3. Global Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 4. Global Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 5. Global Neurological Disorders Diagnostic Market Share (%), By Region, 2017-2031F
• Figure 6. North America Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 8. North America Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 9. North America Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 10. North America Neurological Disorders Diagnostic Market Share (%), By Country, 2017-2031F
• Figure 11. United States Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 13. United States Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 14. United States Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 15. Canada Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 17. Canada Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 18. Canada Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 19. Mexico Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 21. Mexico Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 22. Mexico Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 23. Europe Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 25. Europe Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 26. Europe Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 27. Europe Neurological Disorders Diagnostic Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 30. Germany Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 31. Germany Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 32. France Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 34. France Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 35. France Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 36. Italy Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 38. Italy Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 39. Italy Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 40. United Kingdom Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 42. United Kingdom Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 43. United Kingdom Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 44. Russia Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 46. Russia Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 47. Russia Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 48. Netherlands Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 50. Netherlands Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 51. Netherlands Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 52. Spain Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 54. Spain Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 55. Spain Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 56. Turkey Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 58. Turkey Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 59. Turkey Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 60. Poland Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 62. Poland Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 63. Poland Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 64. South America Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 66. South America Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 67. South America Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 68. South America Neurological Disorders Diagnostic Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 71. Brazil Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 72. Brazil Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 73. Argentina Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 75. Argentina Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 76. Argentina Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 77. Asia-Pacific Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 79. Asia-Pacific Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 80. Asia-Pacific Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 81. Asia-Pacific Neurological Disorders Diagnostic Market Share (%), By Country, 2017-2031F
• Figure 82. India Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 84. India Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 85. India Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 86. China Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 88. China Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 89. China Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 90. Japan Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 92. Japan Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 93. Japan Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 94. Australia Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 96. Australia Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 97. Australia Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 98. Vietnam Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 100. Vietnam Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 101. Vietnam Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 102. South Korea Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 104. South Korea Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 105. South Korea Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 106. Indonesia Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 108. Indonesia Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 109. Indonesia Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 110. Philippines Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 112. Philippines Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 113. Philippines Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 114. Middle East & Africa Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 116. Middle East & Africa Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 117. Middle East & Africa Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 118. Middle East & Africa Neurological Disorders Diagnostic Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 121. Saudi Arabia Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 122. Saudi Arabia Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 123. UAE Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 125. UAE Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 126. UAE Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 127. South Africa Neurological Disorders Diagnostic Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Neurological Disorders Diagnostic Market Share (%), By Product, 2017-2031F
• Figure 129. South Africa Neurological Disorders Diagnostic Market Share (%), By Condition, 2017-2031F
• Figure 130. South Africa Neurological Disorders Diagnostic Market Share (%), By End-User, 2017-2031F
• Figure 131. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Condition Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By End-User Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global neurological disorders diagnostic market is projected to witness a CAGR of 7.56% during the forecast period 2024-2031, growing from USD 7.93 billion in 2023 to USD 14.21 billion in 2031. The market demand for diagnostic neurological disorders is anticipated to thrive drastically in the forecast years due to the rising prevalence of neurological disorders and the growing interest of investors and market players.

Neurological disorders, as a medical term, refers to the disorders that affect the brain besides the nerves distributed all over the human body and the spinal cord. Such disorders may have varied symptoms due to structural, biochemical, or electrical abnormalities in the brain, spinal cord, or other nerves. Examples of such disorders are paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain, and disturbed levels of consciousness. For instance, according to The Lancet Neurology report, over 1 in 3 people around the world are affected by neurological conditions, meaning it is now the leading cause of illness and disability worldwide. While brain diseases, disorders, and injuries affect everyone around the globe, it is estimated that more than 80% of neurological deaths and health loss occur in low-income and middle-income countries. High-income countries have up to 70 times more neurological professionals per 100,000 population than low-and middle-income countries. The prevalence of neurological disorders such as diabetes neuropathy and Alzheimer's disease conditions has led to a greater need for neurological disorders diagnosis. These factors are expected to boost the global neurological disorders diagnostic market during the forecast period.

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is a significant growth driver for the neurological disorder diagnostic market. With the growing prevalence of Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis worldwide, the demand for precise early-stage diagnostic tools to detect such diseases is on the rise. This is particularly true for aging populations whose neurological disorders are on the rise. Higher consciousness among medical practitioners and patients regarding neurological disorders has also increased the demand for more advanced diagnostic solutions. Furthermore, the influx of advanced technologies and methodologies by the service providers in the diagnosis process is increasing the scope of this market for neurological disorder diagnostics. This rising prevalence not only underscores the urgency for effective diagnostics but also drives research and development efforts to improve the tools and techniques used to identify and manage these complex disorders. For instance, on 10 May 2023, Scientists from UNSW Sydney, with collaborators at Boston University developed a tool that shows early promise in detecting Parkinson's disease years before the first symptoms start appearing.

Technological Advancements in Neurological Disorder Testing

Technological advancements in neurological disorder testing are a key growth driver for the neurological disorder diagnostic market. Advances in imaging techniques, such as high-resolution MRI and functional imaging, improve the accuracy and efficiency of diagnosis. Advances in neurophysiological testing, including EEG and QEEG, and evoked potential studies allow for detecting abnormalities in brain and nervous system disorders. Integrating AI and ML into diagnostic processes continues to revamp the landscape by enabling a higher degree of precision in analyzing complex data and facilitating early detection. Such technologies improve diagnostics outcomes and allow for efficient workflows within a clinical setting, thus making it easier for healthcare providers to provide timely and accurate care. Since these progressions continue to rise, there will be robust growth in the market for neurological disorder diagnosis, which will consume the new challenges facing diagnosis methods. For instance, on December 21, 2023, Quibim, a company pioneering in imaging biomarkers for Precision Medicine, received approval from the U.S. Food and Drug Administration for QP-Brain, an AI-based software to identify early-stage neurodegenerative diseases. Most disease detection in this field is through qualitative analysis carried out by radiologists and neurologists. This purely human-centered approach means that neuro diseases are often only detected at their later stages. Healthcare institutions, therefore, need very advanced and versatile quantitative AI-based tools that can also provide secure transfer and storage of patients' data and augment the workflow of clinicians.

Neuroimaging Technologies Segment to Dominate the Neurological Disorders Diagnostic Market

The neuroimaging technologies segment is expected to dominate the neurological disorders diagnostic market during the forecast period. Further, the advancements in neuroimaging technologies and new and innovative technologies by key players in the market are expected to propel market growth. Techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) in neuroimaging form the critical anatomical evidence for accurate and timely diagnosis of all neurological disorders. These methods provide detailed information about the structure and function of the brain, where doctors can find abnormalities attributed to disorders, including Alzheimer's disease, tumors, and stroke. The advancement of imaging technology, from higher resolution to functional imaging modalities, has led to improved diagnostic accuracy and therapeutic planning. Increased neurological disorders and the growing need for early diagnosis further favor this growth in demand for neuroimaging modalities. Healthcare providers will increasingly use advanced imaging techniques to support their diagnoses, so neuroimaging technologies will become extremely important in defining the market's future for neurological disorder diagnostics. For instance, on 27 February 2024, Philips, a global leader in health technology, announced major enhancements to its Image Guided Therapy System - Azurion - with the launch of its new Azurion neuro biplane system. The new image-guided therapy system is a comprehensive interventional solution in patients with stroke or other neurovascular diseases, supporting confident diagnosis, image guidance, and therapy assessment.

North America Dominates Neurological Disorders Diagnostic Market

North America is the biggest market in terms of neurological disorder diagnostics. Generally, the developed health infrastructures, huge investments in research and development, and a high incidence of neurological conditions are dominant in the region. The incidence of chronic neurodegenerative diseases will at least double within the next two decades. In 2023, the two most prevalent neurological diseases were Alzheimer's disease and Parkinson's disease. An estimated 6.7 million Americans 65 years of age and older have Alzheimer's disease. If medical developments are not achieved to prevent, halt, or even cure AD, this number may increase to 13.8 million by the year 2060. In addition, the good network of hospitals and diagnostic centers found in this region have cutting-edge technologies, such as advanced neuroimaging and neurophysiological testing methods, which help in proper and timely diagnosis.

Increased awareness and the advertisement of neurological disorders have led to an increased demand for service diagnosis. The government's increasing initiative through huge investments in researching neurological disorders further fuels the growth of the market toward innovation in diagnostic tools and treatments. For instance, on 30 April 2024, NeuroClues, a French-Belgian medtech company that specializes in the diagnosis of neurodegenerative diseases, announced that it has successfully closed a new funding round of around USD 5 million. It was led by White Fund and the European Commission's EIC Accelerator program, along with existing investors.

Future Market Scenario (2024-2031F)

The future market scenario regarding the neurological disorders diagnostic market is promising with robust growth rates, driven primarily by ongoing technological advancement and a need for faster and more precise diagnoses. These ongoing innovations in neuroimaging, biomarker identification, and artificial intelligence will further evolve; healthcare providers will become more adept at detecting and managing conditions more precisely. The prevalence of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis is expected to continue rising and spreading among elders, boosting market growth even more. There is going to be an increased focus on personalized medicine and a patient-centric approach that would increase the demand for tailor-made diagnostic applications for improving patient outcomes. Continuous awareness and investment in neuro-health and high growth in the market would be seen further changing the diagnostic landscape of neurological disorders in the coming years. For instance, on May 9, 2024, Danaher Corporation, a global science and technology innovator, launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild Traumatic Brain Injury (TBI).

Key Players Landscape and Outlook

Market players like Koninklijke Philips N.S., Thermo Fisher Scientific, Inc., and many more dominate the diagnostic of neurological disorders. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of market players' products. The market fosters several smaller players as well, which operate through collaborations with other players to cater to a larger market.

In March 2024, Beckman Coulter and Fujirebio announced the expansion of their collaboration agreement to facilitate the development of patient-friendly, blood-based neurodegenerative disease diagnostics.

In February 2023, Hyperfine, the pioneering medical device company that developed the Swoop system, the world's first FDA-cleared portable MRI system, announced CE Marking for the product.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Neurological Disorders Diagnostic Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. Diagnostic and Imaging Systems
      • 4.2.1.1.1. Electroencephalogram (EEG) Systems
      • 4.2.1.1.2. Magnetic Resonance Imaging (MRI) Systems
      • 4.2.1.1.3. Magnetic Resonance Imaging (MRI) Systems
      • 4.2.1.1.4. Ultrasound Imaging Systems
      • 4.2.1.1.5. Others
    • 4.2.1.2. In-Vitro Diagnostics (IVD)
      • 4.2.1.2.1. Biomarker
      • 4.2.1.2.2. Biopsy
      • 4.2.1.2.3. Others
  • 4.2.2. By Condition
    • 4.2.2.1. Neuro Degenerative Diseases
    • 4.2.2.2. Stroke
    • 4.2.2.3. Epilepsy
    • 4.2.2.4. Sleep Disorders
    • 4.2.2.5. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals and Clinics
    • 4.2.3.2. Diagnostic Centers
    • 4.2.3.3. Ambulatory Care Centers
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Product
  • 4.3.2. By Condition
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. North Neurological Disorders Diagnostic Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Diagnostic and Imaging Systems
      • 5.2.1.1.1. Electroencephalogram (EEG) Systems
      • 5.2.1.1.2. Magnetic Resonance Imaging (MRI) Systems
      • 5.2.1.1.3. Magnetic Resonance Imaging (MRI) Systems
      • 5.2.1.1.4. Ultrasound Imaging Systems
      • 5.2.1.1.5. Others
    • 5.2.1.2. In-Vitro Diagnostic (IVD)
      • 5.2.1.2.1. Biomarker
      • 5.2.1.2.2. Biopsy
      • 5.2.1.2.3. Others
  • 5.2.2. By Condition
    • 5.2.2.1. Neuro Degenerative Diseases
    • 5.2.2.2. Stroke
    • 5.2.2.3. Epilepsy
    • 5.2.2.4. Sleep Disorders
    • 5.2.2.5. Others
  • 5.2.3. By End-user
    • 5.2.3.1. Hospital and Clinics
    • 5.2.3.2. Diagnostic Centers
    • 5.2.3.3. Ambulatory Care Centers
    • 5.2.3.4. Others
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Neurological Disorders Diagnostic Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Product
        • 5.3.1.2.1.1. Diagnostic and Imaging Systems
      • 5.2.1.1.1. Electroencephalogram (EEG) Systems
      • 5.2.1.1.2. Magnetic Resonance Imaging (MRI) Systems
      • 5.2.1.1.3. Magnetic Resonance Imaging (MRI) Systems
      • 5.2.1.1.4. Ultrasound Imaging Systems
      • 5.2.1.1.5. Others
      • 5.3.1.2.1.2 In-Vitro Diagnostics (IVD)
      • 5.2.1.2.1. Biomarker
      • 5.2.1.2.2. Biopsy
      • 5.2.1.2.3. Others
      • 5.3.1.2.2. By Condition
        • 5.3.1.2.2.1. Neuro Degenerative Diseases
        • 5.3.1.2.2.2. Stroke
        • 5.3.1.2.2.3. Epilepsy
        • 5.3.1.2.2.4. Sleep Disorders
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By End-user
        • 5.3.1.2.3.1. Hospitals and Clinics
        • 5.3.1.2.3.2. Diagnostic Centers
        • 5.3.1.2.3.3. Ambulatory Care Centers
        • 5.3.1.2.3.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Neurological Disorders Diagnostic Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Neurological Disorders Diagnostic Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Neurological Disorders Diagnostic Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Neurological Disorders Diagnostic Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Clinical Trials
• 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Koninklijke Philips N.S.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 21.3.2. Thermo Fisher Scientific, Inc.
  • 21.3.3. CANON MEDICAL SYSTEMS CORPORATION.
  • 21.3.4. FUJIFILM Holdings Corporation.
  • 21.3.5. Bio-Rad Laboratories, Inc.
  • 21.3.6. QIAGEN N.V.
  • 21.3.7. Siemens AG.
  • 21.3.8. Mitsar Co, LTD.
  • 21.3.9. NIHON KOHDEN CORPORATION.
  • 21.3.10. General Electric Company.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer